AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
+1.13 (2.16%)
Real-time:   11:03AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 52.21 - 54.84
52 week 17.18 - 60.84
Open 52.34
Vol / Avg. 146,249.00/680,838.00
Mkt cap 1.63B
P/E 14.31
Div/yield     -
EPS 3.73
Shares 30.53M
Beta 0.22
Inst. own 104%
May 21, 2015
AMAG Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 7, 2015
AMAG Pharmaceuticals Inc at Robert W. Baird & Co. Inc's Growth Stock Conference - 1:40PM EDT - Add to calendar
May 6, 2015
AMAG Pharmaceuticals Inc at Deutsche Bank Health Care Conference - 8:40AM EDT - Add to calendar
May 5, 2015
Q1 2015 AMAG Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 5, 2015
Q1 2015 AMAG Pharmaceuticals Inc Earnings Call - 8:00AM EDT - Add to calendar
Apr 15, 2015
AMAG Pharmaceuticals Inc at Needham Healthcare Conference
Mar 2, 2015
AMAG Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 24, 2015
AMAG Pharmaceuticals Inc at RBC Healthcare Conference
Feb 11, 2015
AMAG Pharmaceuticals Inc at Leerink Global Healthcare Conference
Feb 9, 2015
Q4 2014 AMAG Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 268.54% 109.19%
Operating margin -6.34% -3.08%
EBITD margin - 10.66%
Return on average assets 62.34% 16.42%
Return on average equity 174.63% 42.96%
Employees 257 -
CDP Score - -


1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Officers and directors

Gino Santini Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Frank E. Thomas President, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 40
Bio & Compensation  - Reuters
Scott B. Townsend Esq. Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 47
Bio & Compensation  - Reuters
Linda Lennox Vice President of Investor Relations, & Corporate Communications
Bio & Compensation  - Reuters
Katie Payne Vice President - External Affairs.
Bio & Compensation  - Reuters
John A. Fallon Director
Age: 67
Bio & Compensation  - Reuters
Lesley Russell Cooper Independent Director
Age: 54
Bio & Compensation  - Reuters